基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CStone Pharmaceuticals Selected as a Constituent of HSCI 2021-08-20 20:24
CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA and considered for Priority Review 2021-08-03 08:05
CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021 2021-07-08 08:05
CStone announces China NMPA acceptance of IND application for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody-based molecule, marking further expansion of its Pipeline 2.0 strategy 2021-07-07 08:05
CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer 2021-06-28 08:05
CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication application 2021-06-24 08:05
CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy 2021-06-21 13:06
CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application 2021-05-28 08:10
CStone Announces Acceptance of New Drug Application in Hong Kong for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumor 2021-05-12 14:09
CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R) (Pralsetinib) with Priority Review Designation for the Treatment of Advanced or Metastatic RET-Altered Thyroid Cancer Patients 2021-04-26 21:14
CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor 2021-03-31 18:20
CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020 2021-03-25 22:03
CStone Announces New Drug Approval of GAVRETO(R) (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients 2021-03-24 10:46
CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced RET Fusion-positive Non-Small Cell Lung Cancer after Platinum-based Chemotherapy at IASLC WCLC 2020 2021-01-28 10:15
CStone's Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer 2020-12-10 08:30
ESMO ASIA Congress 2020 | CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC 2020-11-23 09:30
CStone Pharmaceuticals Announces China's NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC 2020-11-12 10:58
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate 2020-10-29 07:15
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1) 2020-10-27 07:23
CStone Announces Completion of $200 million Share Sale to Pfizer 2020-10-12 08:05
1 2 3 4 5 6 8